Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Corbus Pharma (CRBP)

Corbus Pharma (CRBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 454,408
  • Shares Outstanding, K 64,455
  • Annual Sales, $ 4,820 K
  • Annual Income, $ -55,670 K
  • 60-Month Beta 2.01
  • Price/Sales 93.84
  • Price/Cash Flow N/A
  • Price/Book 10.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate 0.22
  • Low Estimate -0.44
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.43 +12.37%
on 06/06/19
7.51 -3.86%
on 05/24/19
-0.15 (-2.04%)
since 05/20/19
3-Month
6.43 +12.37%
on 06/06/19
8.09 -10.75%
on 04/05/19
-0.04 (-0.55%)
since 03/20/19
52-Week
4.50 +60.44%
on 08/08/18
9.11 -20.75%
on 02/15/19
+1.22 (+20.33%)
since 06/20/18

Most Recent Stories

More News
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid...

CRBP : 7.31 (+3.69%)
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid...

CRBP : 7.31 (+3.69%)
SHAREHOLDER ALERT: CRBP FSNN MWA AAPL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

CRBP : 7.31 (+3.69%)
AAPL : 199.37 (+0.76%)
MWA : 10.24 (+1.19%)
FSNN : 0.0580 (-19.44%)
CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

CORT : 10.54 (+0.09%)
CRBP : 7.31 (+3.69%)
NIO : 2.84 (+3.65%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NIO, CRBP, ARA and NTNX

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

ARA : 7.01 (+1.59%)
CRBP : 7.31 (+3.69%)
NTNX : 26.98 (+2.90%)
NIO : 2.84 (+3.65%)
Bronstein, Gewirtz & Grossman, LLC Class Action Update: BPI, CRBP & NIO

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

CRBP : 7.31 (+3.69%)
NIO : 2.84 (+3.65%)
BPI : 6.39 (unch)
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or "the Company") (NASDAQ: CRBP)...

CRBP : 7.31 (+3.69%)
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming May 13, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Corbus Pharmaceuticals...

CRBP : 7.31 (+3.69%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Corbus Pharmaceuticals Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline - CRBP

Pomerantz LLP announces that a class action lawsuit has been filed against Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or the "Company") (NASDAQ: CRBP) and certain of its officers. The class action,...

CRBP : 7.31 (+3.69%)
CLASS ACTION UPDATE for CRCM, CRBP, ARA and MWA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

ARA : 7.01 (+1.59%)
CRBP : 7.31 (+3.69%)
CRCM : 14.17 (-0.21%)
MWA : 10.24 (+1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CRBP with:

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

2nd Resistance Point 7.22
1st Resistance Point 7.14
Last Price 7.31
1st Support Level 6.94
2nd Support Level 6.83

See More

52-Week High 9.11
Fibonacci 61.8% 7.35
Last Price 7.31
Fibonacci 50% 6.80
Fibonacci 38.2% 6.26
52-Week Low 4.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar